Across TCGA pan-cancer cohorts, VSTM1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VSTM1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher VSTM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated VSTM1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BLCA, LUSC, and UCEC are the cancer types where VSTM1 Mutation most reproducibly stratifies survival.